Abstract
This article aimed to assess the effect of botulinum toxin type A (BTX-A), when used in conjunction with physiotherapy, in spasticity management. Patients were assessed before and after BTX-A injection using the following outcome measures: the Medical Research Council (MRC) scale for motor testing; the Modified Ashworth Scale (MAS) for spasticity; the Global Pain Scale (GPS); the modified Barthel score for activities of daily living; spasm frequency; and adductor tone rating. In total, 72 patients (aged 13–81 years; 43% male) received BTX-A treatment. MAS scores were reduced by a median of 1 point (P <0.001) and 56% of patients had a 30% or greater reduction in GPS scores after injection. Mean spasm frequency (per hour) was reduced by 3.1 (P <0.001) and improvements were detected in adductor tone and activities of daily living scores (P <0.001 and P=0.046 respectively) after injection, while MRC scale scores showed statistically significant improvements, particularly in severely impacted categories (P=0.007). Reported improvements in affected joints were made by patients and carers, with benefits lasting an average of 6 months. BTX-A injections were well tolerated. These findings suggest that BTX-A injections have a key role to play in spasticity management.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Therapy and Rehabilitation
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
